Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate whether an investigational monoclonal antibody, CT-011, is safe
to give and if it helps patients with hepatitis C virus (HCV). Monoclonal antibodies are a
type of drug that is typically given by infusion into a vein (intravenously). Results of this
trial will help doctors obtain additional information with regard to the safety and efficacy
of CT-011 as a potential treatment for HCV.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
CureTech Ltd
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries